BioSpace News Archive

Findings confirmed that patient-specific autologous dendritic cell vaccines (DCV) induced a different immune response associated with longer survival than autologous tumor cell vaccines (TCV) – IRVINE, Calif.--( BUSINESS WIRE )-- AIVITA Biomedical, Inc., a biotechnology company specializing in innovative cell therapy applications, announced today the publication of a paper titled, “Cytokine network analysis of immune responses before and after au

Sengenics, a functional proteomics company, today announced the product launch of a new KREX™-based array, the ImmuKyne™ protein array, in a bid to enhance and accelerate effective response for COVID-19 by understanding whether autoantibodies play a role in progression to severe disease in COVID-19 patients, using advanced antibody profiling assays.

The National Association of Specialty Pharmacy (NASP), a nonprofit organization representing specialty pharmacy industry stakeholders, named former NFL quarterback and Pro Football Hall of Fame member Jim Kelly as a keynote speaker for the 2020 NASP Annual Meeting & Expo.

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the company’s drug substance (DS) line and drug product (DP) line for HLX02 trastuzumab biosimilar have successfully passed the European United (EU) Good Manufacturing Practice (GMP) on-site inspection and the company has received two EU GMP Certificates (Certificate of GMP Compliance of a Manufacturer) from Poland’s Chief Pharmaceutical Inspector.

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its audited financial results for the three months ended March 31, 2020 on Thursday, April 30, 2020 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m.

Australian-based company CLINUVEL is launching SCENESSE® in the People’s Republic of China for the treatment of the rare genetic metabolic disorder erythropoietic protoporphyria.

Conformis, Inc. announced that, due in large part to a loan made available to the Company under the Paycheck Protection Program offered by the U.S. Small Business Administration to qualified small businesses in response to the coronavirus pandemic and the economic harm done to the Company’s business, the Company has accelerated its plan to return to full-time employment the vast majority of those employees who were furloughed on March 23, 2020.

Two Virtual Posters Highlight New ANJESO Clinical Results, Along with Health Resource Utilization Data, When Administered Preoperatively Following Total Knee Arthroplasty

During the ongoing COVID-19 pandemic, people across Arkansas are facing challenges that extend beyond medical care and includes basic daily needs.

Annovis Bio Inc., a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases, published data from its two double-blind, placebo controlled animal studies in Alzheimer’s disease and Parkinson’s disease demonstrating in both diseases preclinical efficacy of ANVS401, the company’s lead compound.